Abstract:Abstract Glioblastomas (GBM) are extremely aggressive and have the poorest prognosis among brain tumors. These tumors display extensive microvasculature that presumably originates from endothelial cell angiogenesis. Indeed, many anti-angiogenic therapies have been accepted for glioblastoma treatment based on this premise. Recent evidence has shown that glioblastoma stem-like cells (GSCs) can differentiate into endothelial cells that participate in angiogenesis (Ricci-Vitiani L et al., Nature 2010;468:824-29, Wang et al., Nature 2010;468:829-33, & Soda et al., PNAS 2011; 108:4274-80). However, it remains to be clarified if these GSC-derived endothelial cells make a significant contribution to tumor vasculature. Here, we surveyed eleven GBM cases and found that glioblastomas consisted of 34.1% of endothelial cell-associated vasculature, while 59.7% of microvasculature arose from mural-like tumor cells that co-express mural cell markers smooth muscle alpha actin and platelet-derived growth factor receptor, and VEGF receptor 2 (Flk-1), but not CD31, CD34 or VE-cadherin. This pattern of vascularization indicates an alternative microvascular circulation known as vasculogenic mimicry (VM). GSCs derived from patients with GBM displayed the multipotency of neuronal stem cells capable of transdifferentiation into mural-like tumor cells that promoted VM. GSCs developed vigorous mural cell-associated vascular channels but few endothelial cell vessels in orthotopic brain tumor models. Furthermore, the development of these tumor cell-associated channels was dependent on expression of VEGF receptor 2 (Flk-1). Suppression of Flk-1 activity and gene expression by a variety of different inhibitory approaches abrogated GSC transdifferentiation and vascularization in vitro, and inhibited VM in xenografted tumor models in vivo. Collectively, this study establishes a pivotal role for transdifferentiation of GSCs in the development of VM, which contributes to an aggressive phenotype of GBM, and points to Flk-1 as a potential target for therapeutic intervention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1024. doi:1538-7445.AM2012-1024

Vasculogenic Mimicry–potential Target for Glioblastoma Therapy: an in Vitro and in Vivo Study

Vasculogenic Mimicry: a Novel Target for Glioma Therapy.

Vasculogenic Mimicry Persists During Glioblastoma Xenograft Growth

Transdifferentiation Of Glioblastoma Stem-Like Cells Into Mural Cells Drives Vasculogenic Mimicry In Glioblastomas

Vasculogenic Mimicry Assay of Glioma Stem Cell in Vitro

Clinical Significance of Vasculogenic Mimicry in Human Gliomas

Vasculogenic Mimicry in Subcutaneous Xenograft Glioma Model of Mice

Overview of Advances in Vasculogenic Mimicry - a Potential Target for Tumor Therapy

Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments

Vasculogenic Mimicry and Tumor Stem Cells

The Research Advance on Vasculogenic Mimicry in Glioma

Molecular Regulation of Vasculogenic Mimicry in Tumors and Potential Tumor-Target Therapy

Vasculogenic Mimicry is a Prognostic Factor for Postoperative Survival in Patients with Glioblastoma

Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry

Glioblastoma-derived Tumor Cells Induce Vasculogenic Mimicry through Flk-1 Protein Activation

[Vasculogenic Mimicry--potential Target for Tumor Therapy].

Vasculogenic mimicry in carcinogenesis and clinical applications

Abstract 1024: Mural Cell Transdifferentiation of Glioblastoma Stem-Like Cells Drives Vasculogenic Mimicry in Glioblastoma Development

Preliminary Studies on Cell Derivation of Neovascularization in Human Glioma and Its Functional Evaluation

Galunisertib Inhibits Glioma Vasculogenic Mimicry Formation Induced by Astrocytes

Vasculogenic Mimicry and Tumor Metastasis.